

S 483

Ensuring Patient Access and Effective Drug Enforcement Act of 2016

Congress: 114 (2015–2017, Ended)

Chamber: Senate

Policy Area: Crime and Law Enforcement

Introduced: Feb 12, 2015

Current Status: Became Public Law No: 114-145.

Latest Action: Became Public Law No: 114-145. (Apr 19, 2016)

Law: 114-145 (Enacted Apr 19, 2016)

Official Text: <https://www.congress.gov/bill/114th-congress/senate-bill/483>

Sponsor

Name: Sen. Hatch, Orrin G. [R-UT]

Party: Republican • **State:** UT • **Chamber:** Senate

Cosponsors (4 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Whitehouse, Sheldon [D-RI]	D · RI		Feb 12, 2015
Sen. Rubio, Marco [R-FL]	R · FL		Mar 17, 2015
Sen. Vitter, David [R-LA]	R · LA		Mar 24, 2015
Sen. Cassidy, Bill [R-LA]	R · LA		Apr 22, 2015

Committee Activity

Committee	Chamber	Activity	Date
Judiciary Committee	Senate	Reported By	Feb 11, 2016

Subjects & Policy Tags

Policy Area:

Crime and Law Enforcement

Related Bills

Bill	Relationship	Last Action
114 HR 471	Related bill	Apr 22, 2015: Received in the Senate and Read twice and referred to the Committee on the Judiciary.

(This measure has not been amended since it was reported to the Senate on February 11, 2016. The summary of that version is repeated here.)

Ensuring Patient Access and Effective Drug Enforcement Act of 2016

(Sec. 2) This bill amends the Controlled Substances Act to define phrases related to the Drug Enforcement Administration's (DEA's) authority to register manufacturers, distributors, and dispensers of controlled substances.

Currently, the DEA registers a controlled substances manufacturer, distributor, or dispenser if it is in the public interest after considering certain factors, including factors relevant to and consistent with the public health and safety. This bill defines "factors as may be relevant to and consistent with the public health and safety" to mean factors relevant to and consistent with the specified purposes of the Controlled Substances Act.

Additionally, current law allows the DEA to immediately suspend a registration to prevent imminent danger to the public health and safety. This bill defines "imminent danger to the public health and safety" to mean an immediate threat of death, serious bodily harm, or abuse of a controlled substance due to a registrant's failure to maintain effective controls against diversion.

The bill revises and expands the required elements of an order to show cause issued by the DEA before it denies, revokes, or suspends a registration for a Controlled Substances Act violation. An order to show cause must specifically state the legal basis for the action and notify the registrant of the opportunity to submit a corrective action plan.

(Sec. 3) The Food and Drug Administration, the Substance Abuse and Mental Health Services Administration, the Agency for Research and Quality, and the Centers for Disease Control and Prevention, in coordination with the DEA, must report to Congress on:

- obstacles to legitimate patient access to controlled substances;
- diversion of controlled substances;
- how collaboration between law enforcement agencies and the pharmaceutical industry can benefit patients and prevent diversion and abuse of controlled substances;
- the availability of and gaps in medical education, training opportunities, and comprehensive clinical guidance for pain management and opioid prescribing;
- enhancements to prescription drug monitoring programs; and
- improvements to prescription opioid reporting requirements.

Actions Timeline

- **Apr 19, 2016:** Signed by President.
- **Apr 19, 2016:** Became Public Law No: 114-145.
- **Apr 14, 2016:** Presented to President.
- **Apr 12, 2016:** Mr. Lance asked unanimous consent to take from the Speaker's table and consider.
- **Apr 12, 2016:** Considered by unanimous consent. (consideration: CR H1618-1619)
- **Apr 12, 2016:** Passed/agreed to in House: On passage Passed without objection.(text: CR H1618-1619)
- **Apr 12, 2016:** On passage Passed without objection. (text: CR H1618-1619)
- **Apr 12, 2016:** Motion to reconsider laid on the table Agreed to without objection.
- **Mar 21, 2016:** Received in the House.
- **Mar 21, 2016:** Held at the desk.
- **Mar 18, 2016:** Message on Senate action sent to the House.
- **Mar 17, 2016:** Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.(consideration: CR S1605-1606; text as passed Senate: CR S1605-1606)
- **Mar 17, 2016:** Passed Senate with an amendment by Unanimous Consent. (consideration: CR S1605-1606; text as passed Senate: CR S1605-1606)
- **Feb 11, 2016:** Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
- **Feb 11, 2016:** Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.
- **Feb 11, 2016:** Placed on Senate Legislative Calendar under General Orders. Calendar No. 368.
- **Feb 12, 2015:** Introduced in Senate
- **Feb 12, 2015:** Read twice and referred to the Committee on the Judiciary.